KRAS and colorectal carcinoma: Several activation-type KRAS variations are observed in the group positive for the protein expression of ARID1A. The existence of ARID1A variations (44%) and KRAS variations (48%) has been demonstrated in stage I–III CRC (Fountzilas et al. 2018).